Demographics and Risk Profile of Elderly Middle Eastern Patients with Atrial Fibrillation: The Jordan Atrial Fibrillation (JoFib) Study

Figures & data

Table 1 Demographics and Clinical Characteristics of Middle Eastern Patients with Atrial Fibrillation

Clinical Feature	Age ≥80 (n=379)	Age <80 (n=1784)	P-value
Age in years (mean ± SD)	84.1 ± 3.7	64.4 ± 11.8
Female	216 (57.0%)	949 (53.2%)	0.18
Hypertension	303 (79.9%)	1312 (73.5%)	0.01
Diabetes Mellitus	166 (43.8%)	787 (44.1%)	0.91
Hypercholesterolemia	168 (44.3%)	809 (45.3%)	0.72
Current cigarette smoker	19 (5.0%)	271 (15.2%)	<0.001
BMI (Kg/m^2), mean ± SD	28.1 ± 5.5	29.8 ± 6.2	<0.001
<25	110 (31.2%)	351 (21.6%)
25–29	137 (38.8%)	575 (35.3%)
>30	106 (30.0%)	702 (43.1%)	<0.001
Comorbidities:
Stroke or systemic embolization	97 (25.6%)	263 (14.7%)	<0.001
Heart failure	115 (30.3%)	409 (22.9%)	0.002
LV hypertrophy	141 (41.5%)	636 (39.4%)	0.57
Coronary artery disease	33 (8.7%)	204 (11.4%)	0.12
LVEF<40%	50 (14.2%)	234 (13.8%)	0.85
Pulmonary hypertension	115 (30.6%)	441 (24.8%)	0.0.02
Sleep apnea	12 (3.2%)	90 (5.0%)	0.12
Thyroid disease	47 (12.4%)	183 (10.3%)	0.22
Chronic kidney disease	51 (13.5%)	148 (8.3%)	0.002
ESRD on dialysis	2 (0.5%)	7 (0.4%)	0.71
Active malignancy	22 (5.8%)	94 (5.3%)	0.68
Paroxysmal AF	100 (26.4%)	673 (37.8)	<0.001
Valvular AF	9 (2.4%)	174 (9.8%)	<0.001
Antiplatelet agent	124 (32.7%)	776 (43.5%)	<0.001

Notes: Pulmonary hypertension: systolic pulmonary artery pressure > 25 mmHg by continuous wave Doppler peak velocity of the tricuspid valve. Chronic kidney disease: Estimated glomerular filtration rate < 60 mL/min/1.73 m2. Thyroid disease: A prior diagnosis of hypo- or hyperthyroidism.

Abbreviations: AF, atrial fibrillation; BMI, body mass index; LVEF, left ventricular ejection fraction; ESRD, end stage renal disease.

Figure 1 CHA2DS2-VASc score in the two age groups of patients with non-valvular atrial fibrillation (NVAF).

Figure 2 The HAS-BLED score in the two age groups of patients with non-valvular atrial fibrillation (NVAF).

Table 2 The Utilization of Oral Anticoagulation in Patients with Non-Valvular Atrial Fibrillation

	Age ≥80 Years		Age <80 Years		P-value
	N = 370		N = 1608
Eligible for OACs	330	89.2%	1204	85.9%	0.13
Use of OACs in eligible patients	278	84.2%	1133	84.3%	0.96
DOACs in eligible patients	201	72.3%	706	62.3%	<0.001
VKA in eligible patients	77	27.7%	427	37.7%	<0.001

Notes: Eligibility for OAC was based on CHA2DS2-VASc score of 2 or more in men and 3 or more in women.

Abbreviations: DOACs, direct oral anti-coagulant agents; VKA, vitamin K antagonist.